FarmaKology-Diabetes and Obesity Drugs May Reduce Risk of Dementia for Older Diabetes Patients

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "[email protected]", and happy to have you featured on our newsletter+21K Subs.

Today's Company

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

News

Acino signs an exclusive licensing and supply agreement with Allecra Therapeutics in Gulf Cooperation Council countries and South Africa

Allecra Therapeutics and Acino today announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP? (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024. In addition, the companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the above territories.

4D Molecular Therapeutics to Kick off Phase I Gene Therapy Trial for Geographic Atrophy

4D Molecular Therapeutics, a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced U.S. Food and Drug Administration clearance of the Investigational New Drug Application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with GA.

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.

Takeda Announces Approval of LIVTENCITY? (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda today announced that LIVTENCITY? (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies. LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.

Research & Study

New study demonstrates the efficacy of a promising celiac disease drug at the molecular level

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

Diabetes and Obesity Drugs May Reduce Risk of Dementia For Older Diabetes Patients

Sarecycline May Be Effective in Periorificial Dermatitis Treatment

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Management of common skin conditions and ailments in the community pharmacy

Rethinking Emerging Biopharma’s Relationships with CROs

Video